New treatment for high-risk CLL using two medicines plus chemo-free pills
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding acalabrutinib to obinutuzumab plus venetoclax works better than the standard combo (obinutuzumab plus venetoclax) for people with untreated, high-risk CLL. It’s designed to see if the stronger mix can improve control of the leukemia with an acceptable safety profile.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older, and you have CLL/SLL that needs treatment now (not just watch-and-wait).
- Your CLL is “high risk,” such as 17p deletion, TP53 mutation, complex chromosome changes, or an unmutated IGHV gene.
- Your general health is good enough to take study treatment (ECOG performance status 0 to 2).
- Your organs are working well enough for safe treatment: platelets >30, kidney function (creatinine clearance) ≥30, and liver blood tests not too high.
- You must test negative for hepatitis B and C in a specific way, and you must have no active uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies how well acalabrutinib works when combined with either venetoclax or obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL). It aims to improve disease control while checking safety and tolerability.
This Phase 2 study tests venetoclax plus obinutuzumab, and whether adding acalabrutinib (or not) improves outcomes for people with relapsed or refractory CLL/SLL. It aims to see which combination works best and is safe for patients whose leukemia has returned or not responded.
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
This study tests acalabrutinib together with obinutuzumab in people with newly diagnosed chronic lymphocytic leukemia (CLL) to see how well the combination works. It may help by improving control of the cancer, but you’ll be closely monitored for side effects.
This trial tests a new combination of drugs (sonrotoclax plus zanubrutinib) against another standard combination (venetoclax plus acalabrutinib) for people with chronic lymphocytic leukemia (CLL) who have not had treatment before. The goal is to see which combination works better.
This trial tests a combination of three drugs (nemtabrutinib, venetoclax, and obinutuzumab) for people with CLL or SLL who need treatment but haven't taken similar targeted therapies before. It aims to see if this new cocktail works better together.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.